Novo Nordisk A/S (NVO) PE Ratio: 10.18
Is Novo Nordisk A/S’s P/E ratio high or low?
Novo Nordisk A/S's P/E ratio of 10.18 is 68% below its 5-year average of 32.00, near the low end of its 5-year range (9.60–50.93).
As of Wednesday, June 17, 2026. 28.19% below its 12-month average of 14.18.
PE Ratio (10.18) = Close Price ($43.52) / Diluted TTM EPS ($4.28)
NVO PE Ratio Chart
NVO Average PE Ratio Chart
NVO Current vs Average PE Ratio Chart
NVO PE Ratio Metrics
PE RATIO
10.18
PE RATIO AVG TTM
14.18
PE RATIO AVG 3Y
29.95
PE RATIO AVG 5Y
32.00
PE RATIO AVG 10Y
26.75
PE RATIO AVG 15Y
25.10
PE RATIO AVG 20Y
23.81
CURRENT VS TTM AVG
-28.19%
CURRENT VS 3Y AVG
-66.01%
CURRENT VS 5Y AVG
-68.18%
CURRENT VS 10Y AVG
-61.95%
CURRENT VS 15Y AVG
-59.45%
CURRENT VS 20Y AVG
-57.24%
NVO Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 10.18 | 14.18 | 29.95 | 32.00 |
| Amgen Inc. (AMGN)vs › | $187.59B | 24.21 | 25.02 | 29.67 | 26.38 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 25.98 | 29.23 | 32.49 | 31.19 |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 17.33 | 21.24 | 157.50 | 109.72 |
| Abbott Laboratories (ABT)vs › | $157.84B | 25.24 | 19.41 | 27.85 | 28.17 |
| Pfizer Inc. (PFE)vs › | $148.41B | 19.88 | 16.39 | 22.47 | 18.18 |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 50.55 | 65.53 | 74.84 | 71.72 |
| Danaher Corporation (DHR)vs › | $128.06B | 35.08 | 41.54 | 38.69 | 34.95 |
| CVS Health Corporation (CVS)vs › | $127.73B | 44.37 | 82.27 | 37.84 | 30.86 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $116.49B | 27.22 | 29.48 | 29.27 | 27.27 |
P/E vs. its own history
At 10.2, P/E is cheaper than usual, sitting higher than 0% of its 20-year history.
20-year low
9.6
median
24.8
20-year high
50.9
P/E Comparison
Trailing P/E
10.2
Forward P/E
N/A
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$43.52
Forward EPS (Est.)
$21.64
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
Novo Nordisk A/S PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S PE Ratio FAQ
- What is the P/E ratio for Novo Nordisk A/S (NVO)?
- The P/E ratio for NVO stock is 10.18.
- Is Novo Nordisk A/S's P/E ratio high or low?
- Novo Nordisk A/S's P/E ratio of 10.18 is 68% below its 5-year average of 32.00, near the low end of its 5-year range (9.60–50.93).
- What is the TTM average P/E ratio for Novo Nordisk A/S (NVO)?
- The TTM average P/E ratio for NVO stock is 14.18.
- What is the 3Y average P/E ratio for Novo Nordisk A/S (NVO)?
- The 3Y average P/E ratio for NVO stock is 29.95.
- What is the 5Y average P/E ratio for Novo Nordisk A/S (NVO)?
- The 5Y average P/E ratio for NVO stock is 32.00.
- What is the 10Y average P/E ratio for Novo Nordisk A/S (NVO)?
- The 10Y average P/E ratio for NVO stock is 26.75.
- What is the 15Y average P/E ratio for Novo Nordisk A/S (NVO)?
- The 15Y average P/E ratio for NVO stock is 25.10.
- What is the 20Y average P/E ratio for Novo Nordisk A/S (NVO)?
- The 20Y average P/E ratio for NVO stock is 23.81.
Novo Nordisk A/S PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-17 | 10.18 |
| 2026-06-16 | 10.19 |
| 2026-06-15 | 10.27 |
| 2026-06-12 | 10.27 |
| 2026-06-11 | 10.28 |
| 2026-06-10 | 10.02 |
| 2026-06-09 | 9.87 |
| 2026-06-08 | 9.60 |
| 2026-06-05 | 10.05 |
| 2026-06-04 | 10.24 |
| 2026-06-03 | 9.83 |
| 2026-06-02 | 10.04 |
| 2026-06-01 | 10.31 |
| 2026-05-29 | 10.66 |
| 2026-05-28 | 10.65 |
| 2026-05-27 | 10.42 |
| 2026-05-26 | 10.34 |
| 2026-05-22 | 10.52 |
| 2026-05-21 | 10.38 |
| 2026-05-20 | 10.54 |
| 2026-05-19 | 10.36 |
| 2026-05-18 | 10.36 |
| 2026-05-15 | 10.47 |
| 2026-05-14 | 10.71 |
| 2026-05-13 | 11.01 |
| 2026-05-12 | 11.00 |
| 2026-05-11 | 10.86 |
| 2026-05-08 | 10.78 |
| 2026-05-07 | 10.71 |
| 2026-05-06 | 10.71 |
| 2026-05-05 | 12.68 |
| 2026-05-04 | 12.55 |
| 2026-05-01 | 12.40 |
| 2026-04-30 | 11.93 |
| 2026-04-29 | 11.39 |
| 2026-04-28 | 11.64 |
| 2026-04-27 | 11.64 |
| 2026-04-24 | 11.64 |
| 2026-04-23 | 10.89 |
| 2026-04-22 | 11.06 |
| 2026-04-21 | 11.14 |
| 2026-04-20 | 11.43 |
| 2026-04-17 | 11.45 |
| 2026-04-16 | 11.57 |
| 2026-04-15 | 11.53 |
| 2026-04-14 | 11.11 |
| 2026-04-13 | 10.73 |
| 2026-04-10 | 10.60 |
| 2026-04-09 | 10.58 |
| 2026-04-08 | 10.63 |
| 2026-04-07 | 10.43 |
| 2026-04-06 | 10.36 |
| 2026-04-02 | 10.45 |
| 2026-04-01 | 10.31 |
| 2026-03-31 | 10.39 |
| 2026-03-30 | 9.97 |
| 2026-03-27 | 10.19 |
| 2026-03-26 | 10.29 |
| 2026-03-25 | 10.27 |
| 2026-03-24 | 10.43 |
| 2026-03-23 | 10.41 |
| 2026-03-20 | 10.32 |
| 2026-03-19 | 10.48 |
| 2026-03-18 | 10.58 |
| 2026-03-17 | 10.86 |
| 2026-03-16 | 10.90 |
| 2026-03-13 | 10.73 |
| 2026-03-12 | 10.75 |
| 2026-03-11 | 10.97 |
| 2026-03-10 | 10.94 |
| 2026-03-09 | 11.24 |
| 2026-03-06 | 10.90 |
| 2026-03-05 | 11.04 |
| 2026-03-04 | 10.88 |
| 2026-03-03 | 10.36 |
| 2026-03-02 | 10.67 |
| 2026-02-27 | 10.58 |
| 2026-02-26 | 10.63 |
| 2026-02-25 | 10.78 |
| 2026-02-24 | 10.91 |
| 2026-02-23 | 11.20 |
| 2026-02-20 | 13.40 |
| 2026-02-19 | 13.69 |
| 2026-02-18 | 13.91 |
| 2026-02-17 | 13.95 |
| 2026-02-13 | 14.01 |
| 2026-02-12 | 13.83 |
| 2026-02-11 | 13.77 |
| 2026-02-10 | 13.88 |
| 2026-02-09 | 13.95 |
| 2026-02-06 | 13.46 |
| 2026-02-05 | 12.25 |
| 2026-02-04 | 13.34 |
| 2026-02-03 | 14.22 |
| 2026-02-02 | 17.00 |
| 2026-01-30 | 17.14 |
| 2026-01-29 | 17.11 |
| 2026-01-28 | 17.40 |
| 2026-01-27 | 18.14 |
| 2026-01-26 | 18.46 |
| 2026-01-23 | 17.96 |
| 2026-01-22 | 17.95 |
| 2026-01-21 | 17.11 |
| 2026-01-20 | 17.50 |
| 2026-01-16 | 17.98 |
| 2026-01-15 | 16.48 |
| 2026-01-14 | 16.99 |
| 2026-01-13 | 17.20 |
| 2026-01-12 | 17.27 |
| 2026-01-09 | 16.96 |
| 2026-01-08 | 16.54 |
| 2026-01-07 | 16.32 |
| 2026-01-06 | 16.23 |
| 2026-01-05 | 15.90 |
| 2026-01-02 | 15.11 |
| 2025-12-31 | 14.68 |
| 2025-12-30 | 14.77 |
| 2025-12-29 | 14.85 |
| 2025-12-26 | 15.12 |
| 2025-12-24 | 15.16 |
| 2025-12-23 | 14.89 |
| 2025-12-22 | 13.87 |
| 2025-12-19 | 13.87 |
| 2025-12-18 | 13.73 |
| 2025-12-17 | 13.78 |
| 2025-12-16 | 14.12 |
| 2025-12-15 | 14.53 |
| 2025-12-12 | 14.47 |
| 2025-12-11 | 14.51 |
| 2025-12-10 | 14.15 |
| 2025-12-09 | 13.37 |
| 2025-12-08 | 13.49 |
| 2025-12-05 | 13.81 |
| 2025-12-04 | 13.84 |
| 2025-12-03 | 13.72 |
| 2025-12-02 | 13.68 |
| 2025-12-01 | 13.97 |
| 2025-11-28 | 14.24 |
| 2025-11-26 | 14.05 |
| 2025-11-25 | 13.57 |
| 2025-11-24 | 12.97 |
| 2025-11-21 | 13.74 |
| 2025-11-20 | 13.73 |
| 2025-11-19 | 14.13 |
| 2025-11-18 | 13.72 |
| 2025-11-17 | 13.98 |
| 2025-11-14 | 13.92 |
| 2025-11-13 | 14.18 |
| 2025-11-12 | 14.50 |
| 2025-11-11 | 14.18 |
| 2025-11-10 | 13.25 |
| 2025-11-07 | 13.18 |
| 2025-11-06 | 13.42 |
| 2025-11-05 | 13.98 |
| 2025-11-04 | 13.13 |
| 2025-11-03 | 13.37 |
| 2025-10-31 | 13.46 |
| 2025-10-30 | 13.62 |
| 2025-10-29 | 13.98 |
| 2025-10-28 | 14.17 |
| 2025-10-27 | 14.39 |
| 2025-10-24 | 14.41 |
| 2025-10-23 | 14.49 |
| 2025-10-22 | 14.53 |
| 2025-10-21 | 14.91 |
| 2025-10-20 | 15.17 |
| 2025-10-17 | 14.80 |
| 2025-10-16 | 15.26 |
| 2025-10-15 | 15.44 |
| 2025-10-14 | 15.42 |
| 2025-10-13 | 15.65 |
| 2025-10-10 | 15.49 |
| 2025-10-09 | 15.97 |
| 2025-10-08 | 16.22 |
| 2025-10-07 | 16.06 |
| 2025-10-06 | 16.23 |
| 2025-10-03 | 16.23 |
| 2025-10-02 | 15.99 |
| 2025-10-01 | 16.10 |
| 2025-09-30 | 15.10 |
| 2025-09-29 | 15.10 |
| 2025-09-26 | 15.13 |
| 2025-09-25 | 15.25 |
| 2025-09-24 | 15.99 |
| 2025-09-23 | 16.20 |
| 2025-09-22 | 16.52 |
| 2025-09-19 | 16.71 |
| 2025-09-18 | 16.83 |
| 2025-09-17 | 15.84 |
| 2025-09-16 | 15.57 |
| 2025-09-15 | 15.14 |
| 2025-09-12 | 14.93 |
| 2025-09-11 | 14.78 |
| 2025-09-10 | 14.80 |
| 2025-09-09 | 14.78 |
| 2025-09-08 | 14.77 |
| 2025-09-05 | 15.03 |
| 2025-09-04 | 15.28 |
| 2025-09-03 | 15.44 |
| 2025-09-02 | 15.34 |
| 2025-08-29 | 15.37 |
| 2025-08-28 | 15.27 |
| 2025-08-27 | 15.36 |
| 2025-08-26 | 15.06 |
| 2025-08-25 | 15.33 |
| 2025-08-22 | 15.51 |
| 2025-08-21 | 15.09 |
| 2025-08-20 | 14.78 |
| 2025-08-19 | 14.91 |
| 2025-08-18 | 14.63 |
| 2025-08-15 | 14.26 |
| 2025-08-14 | 13.87 |
| 2025-08-13 | 13.85 |
| 2025-08-12 | 13.55 |
| 2025-08-11 | 13.57 |
| 2025-08-08 | 13.90 |
| 2025-08-07 | 13.27 |
| 2025-08-06 | 12.35 |
| 2025-08-05 | 13.96 |
| 2025-08-04 | 14.43 |
| 2025-08-01 | 14.25 |
| 2025-07-31 | 13.92 |
| 2025-07-30 | 14.79 |
| 2025-07-29 | 15.95 |
| 2025-07-28 | 20.40 |
| 2025-07-25 | 21.20 |
| 2025-07-24 | 20.91 |
| 2025-07-23 | 20.71 |
| 2025-07-22 | 19.75 |
| 2025-07-21 | 19.20 |
| 2025-07-18 | 19.01 |
| 2025-07-17 | 19.30 |
| 2025-07-16 | 19.82 |
| 2025-07-15 | 19.88 |
| 2025-07-14 | 20.38 |
| 2025-07-11 | 20.38 |
| 2025-07-10 | 21.00 |
| 2025-07-09 | 20.61 |
| 2025-07-08 | 20.59 |
| 2025-07-07 | 20.50 |
| 2025-07-03 | 20.45 |
| 2025-07-02 | 20.64 |
| 2025-07-01 | 20.64 |
| 2025-06-30 | 20.41 |
| 2025-06-27 | 20.26 |
| 2025-06-26 | 20.02 |
| 2025-06-25 | 19.91 |
| 2025-06-24 | 20.91 |
| 2025-06-23 | 20.61 |
| 2025-06-20 | 21.81 |
| 2025-06-18 | 21.88 |
| 2025-06-17 | 21.98 |
| 2025-06-16 | 22.77 |
| 2025-06-13 | 23.60 |
| 2025-06-12 | 23.96 |
| 2025-06-11 | 23.28 |
| 2025-06-10 | 23.46 |
| 2025-06-09 | 22.31 |
| 2025-06-06 | 22.07 |
| 2025-06-05 | 21.48 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar